Groups: Toxicogenomics Unit, Center for Toxicology and Health Safety, National Institute of Public Health, Prague, Czech Republic
Laboratory of Pharmacogenomics, Biomedical Center, Faculty of Medicine in Pilsen
Charles University, Pilsen, Czech Republic
Key members: Pavel Soucek, Radka Vaclavikova, Veronika Brynychova, Viktor Hlavac, Alzbeta Kloudova
Contact: Pavel Soucek,
Research activities: we are involved in the study and development of prognostic and predictive biomarkers for more refined evaluation of survival of cancer patients and the response of tumor cells to the therapy. Genomic, epigenomic, proteomic, and metabolomic analyses of tissue preparations and blood fractions from cancer patients provided by clinical collaborators from the Czech Republic are performed for this purpose. Predictive biomarkers may help clinicians in the stratification of patients into different therapeutic regimens. Discovery and validation of prognostic biomarkers may also contribute to the invention of drugs for targeted therapy. We are currently interested in role of physiological substrates, e.g., oxysterols in cancer etiology, progression, and therapy outcome. For this purpose we launched studies in the genetic, transcriptomic, and metabolomic area supported by national projects.
Key papers related to ENOR:
Selective changes in cholesterol metabolite levels in plasma of breast cancer patients after tumor removal. Soucek P, Vrana D, Ueng YF, Wei S, Kozevnikovova R, Guengerich FP. Clin Chem Lab Med. 2017 Sep 15. pii: /j/cclm.ahead-of-print/cclm-2017-0409/cclm-2017-0409.xml. doi: 10.1515/cclm-2017-0409. [Epub ahead of print].
The Role of Oxysterols in Human Cancer. Kloudova A, Guengerich FP, Soucek P. Trends Endocrinol Metab. 2017;28(7):485-496.
Expression of oxysterol pathway genes in oestrogen-positive breast carcinomas. Kloudova A, Brynychova V, Vaclavikova R, Vrana D, Gatek J, Mrhalova M, Kodet R, Soucek P. Clin Endocrinol (Oxf). 2017;86(6):852-861.